REFERENCES
7.0 REFERENCES


• Borst SI, Lockwood CH. (1975) *Plasma level studies on different brands of sodium diphenylhydantoin (DPH) and primidone.* Int J Clin Pharmacol Biopharm. 12(3): 309-14


• CDER. (1997) *Draft guidance: In-vivo bioequivalence studies based on population and individual bioequivalence approaches.* CDER, Food and Drug Administration, October 1997.


• Chapman AG, Meldrum BS, Mendes E. (1983) *Acute anticonvulsant activity of structural analogues of valproic acid and changes in brain GABA and aspartate content.* Life Sci. 32(17): 2023-31


- Epilim Tablets http://emc.medicines.org.uk/ Date of revision of Text March 2004; Sanofi-Synthelabo, PO Box 597, Guildford, Surrey


MacDonald JT. (1987) Breakthrough seizure following substitution of Depakene capsules (Abbott) with a generic product. Neurology. 37(12): 1885


• Physicians' Desk Reference (PDR), Product information on 'Depakene' ed: 58, 2004 pg 425-429.


- Schwartz PG (1989). *Problems in anticonvulsant switching appear to continue.* Am Epilepsy Digest. 6: 15


• Vadney VJ and Kraushaar KW (1997). *Effects of switching from Depakene to generic valproic acid on individuals with mental retardation* Ment Retad. 35:468-472


• Williams, R. L., Adams, W., Chen, M. L., Hare, D., Hussain, A., Lesko, L. (2000) *Where are we now and where do we go next in terms of the scientific basis for regulation on bioavailability and bioequivalence?* Eur. J. Drug Metab. Pharmacokinet. 25: 7-12


